openPR Logo
Press release

Exclusive speaker interviews with Merck and Sanofi released for Injectable Drug Delivery 2019

03-29-2019 03:45 PM CET | Health & Medicine

Press release from: SMi Group

Exclusive speaker interviews with Merck and Sanofi released

Senior industry experts from Merck and Sanofi will be presenting at Injectable Drug Delivery 2019 in London.

SMi’s Injectable Drug Delivery Conference is returning to London on the 15th and 16th May for its 2nd successful year. The 2019 agenda features a series of in-depth presentations from industry experts, which offers attendees a chance to learn about innovative injectable drug delivery systems with industrial insights in the following areas:

• Life cycle management for developing devices that are both user friendly and revenue effective
• Device design considerations
• Long acting injectables and bringing these therapeutics to market with case studies
• Connected devices, GDPR and cyber security programs
• Developments in primary packaging
• Growth in transdermal delivery and subcutaneous infusion devices
• Digital health partnerships

For those interested in attending, there is a £200 Early Bird discount expiring on Friday 29th March 2019. Places can be reserved at http://www.injectable-drug-delivery.com/openpr5

In the run up to the conference, SMi Group caught up with Quentin Le Masne, Head of Engineering team - Electro-Medical, Drug Delivery Devices, Merck, to get his thoughts and perspectives on the latest developments in injectable drug delivery, as well as the upcoming conference.

A snapshot of Quentin Le Masne’s exclusive interview:
Q: What do you think are the most exciting emerging technologies?
A: “Technologies that allows to remove the needle in parental drug delivery applications, like needlefree bolus injection and passive infusion using patches, while not creating additional fears & challenges. Many companies are now claiming that connectivity is the only bright star in the years to come, but I tend to disagree slightly: we can connect all the devices in the world and most patients will still be afraid of injecting with a needle. Therefore, design team claiming to be patient-centric should focus first and foremost on ways to remove the needle from the equation.”
Q: Are there any sessions you are particularly looking forward to and why?
A: “Particularly interested by the views on EU MDR transition, the impact from global regulatory environment evolution on the drug delivery devices filing. This has a massive potential impact on all marketed devices out there and I will be interested to see what are the different strategies of companies facing this challenge.”

SMi Group also interviewed Vasco Filipe, Senior research scientist - Formulation Development, Sanofi to gain his perspectives on the current challenges facing the industry, technological advancements, his upcoming presentation and his role.

A snapshot of Vasco Filipe’s exclusive interview:
Q: What do you think are the most exciting emerging technologies?
A: “In a world where automation and digitalization are on the rise, I am looking forward to see the extent of how it will impact the pharmaceutical industry. High throughput and robustness are key elements in this field and automation really makes a difference here. Compared to other industries, the development of biopharmaceuticals is relatively recent, and we are lucky to be able to benefit from the fast technological evolution that we’ve been seeing in the last few decades. We have several new analytical tools that allow us to see more and better, robots that can prepare formulations and samples for us, manufacturing practices that are being optimized and simplified, etc. For instance, the arrival of continuous bioprocessing is a good example of something to be excited for.”
Q: Are there any sessions you are particularly looking forward to and why?
A: “There are several promising talks in the program, but the ones that are more closely related to my field are the ones in the manufacturing, filling and quality control session.”

The full speaker interviews and other content such as the two-day agenda and speaker line up is available online at http://www.injectable-drug-delivery.com/openpr5

Injectable Drug Delivery
Date: 15th – 16th May 2019
Workshops: 14th May 21019
Location: Copthorne Tara Hotel Kensington, London UK

---ENDS---

Contact Information:
For all media inquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Road

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exclusive speaker interviews with Merck and Sanofi released for Injectable Drug Delivery 2019 here

News-ID: 1679794 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Merck

Swine Fever Vaccine Market Detailed in New Research Report By 2032 | Merck & Co. …
🚀 𝐒𝐰𝐢𝐧𝐞 𝐅𝐞𝐯𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟗% (𝟐𝟎𝟐𝟓 - 𝟐𝟎𝟑𝟐) The Swine Fever Vaccine Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through - » 70% efforts of Primary Research » 15% efforts of Secondary Research » 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited companies 📈
Women's Health Market Industry Growth Report to 2031 Merck KGaA, Merck & Co, Fer …
[New York, December 2024] Women's Health encompasses a broad spectrum of medical and wellness services tailored to address the unique health needs of women across all life stages. This crucial sub-market of healthcare highlights the necessity for specialized treatments, preventive care, and holistic wellness approaches that resonate with today's female patients. Women's Health isn't just a niche sector; it represents a burgeoning field within healthcare, mirrored by an increasing global
Laboratory Syringe Market Size, Growing Demand to 2036 GESERCO, Merck Millipore, …
A laboratory syringe is a precise instrument commonly used for the accurate measurement and transfer of liquids or gases in scientific experiments. Unlike standard medical syringes, laboratory syringes are often made of materials such as glass or high-quality plastic to withstand chemical reactions and offer greater clarity for observing contents. They come in a range of sizes, from as small as 1 mL to over 100 mL, and are often
Leuprorelin Acetate Market Analysis By Top Keyplayers - Merck, Takeda, MediGene, …
The "Leuprorelin Acetate Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Leuprorelin Acetate Market, 2024-2031 Verified Market Research's most recent report, "Leuprorelin Acetate Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth
Avelumab Market Analysis By Top Key Players - Merck, Pfizer, Merck
The "Avelumab Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Avelumab Market, 2024-2031 Verified Market Research's most recent report, "Avelumab Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the
Nanobodies Market to See Booming Growth 2021-2028 | Novo Nordisk A/S, Merck & Co …
𝐍𝐚𝐧𝐨𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 top level players are analyzed in report based on current and future development status, and Nanobodies market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI. The Nanobodies market report analyse the manufacturing cost of the